The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells. Issue 20 (29th August 2019)

• Record Type: Journal Article
• Authors: Wang, Qixue; Liu, Xing; Zhou, Junhu; Yang, Chao; Wang, Guangxiu; Tan, Yanli; Wu, Ye; Zhang, Sijing; Yi, Kaikai; Kang, Chunsheng
• Is Part Of: Advanced science. Volume 6:Issue 20(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-08-29
• Subjects: collateral effect -- CRISPR‐Cas13a -- EGFRvIII -- glioblastoma (GBM); Science -- Periodicals; 505
• DOI: 10.1002/advs.201901299
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: RNA is rarely used as a therapeutic target due to its flexible structure and instability. CRISPR‐Cas13a is a powerful tool for RNA knockdown, and the potential application of CRISPR‐Cas13a in cancer cells should be further studied. In this study, overexpression of LwCas13a by lentivirus in glioma cells reveals that crRNA‐EGFP induces a "collateral effect" after knocking down the target gene in EGFP‐expressing cells. EGFRvIII is a unique EGFR mutant subtype in glioma, and the CRISPR‐Cas13a system induces death in EGFRvIII‐overexpressing glioma cells. Bulk and single‐cell RNA sequencing analysis in U87‐Cas13a‐EGFRvIII cells confirm the collateral effect of the CRISPR‐Cas13a system. Furthermore, CRISPR‐Cas13a inhibits the formation of glioma intracranial tumors in mice. The results demonstrate the collateral effect of the CRISPR‐Cas13a system in cancer cells and the powerful tumor‐eliminating potential of this system. Abstract : It is reported that a CRISPR/Cas13a system can exert a collateral effect after target recognition in glioma cells, indicating that the CRISPR/Cas13a system has great potential value for tumor elimination, especially for patients with specific oncogene mutations.